OBJECTIVE: To compare the frequency and type of neurological complications after bone marrow transplantation (BMT) with an HLA identical unrelated donor or a mismatched related donor (alternative donors) to the neurological complications after matched sibling BMT for standard and high risk leukaemia or myelodysplastic syndromes. METHODS: Retrospective analysis of consecutively treated patients with (a) BMT from alternative donors (n=39), (b) treated with matched sibling BMT for standard risk leukaemia, myelodysplastic syndromes, or aplastic anaemia (n=53), and (c) treated with matched sibling BMT for high risk leukaemia, myelodysplastic syndromes, or aplastic anaemia (n=49). RESULTS: A total of 72 neurological complications were found. Most of these occurred within the first 6 months after transplant. Thirty six patients developed a severe neurological complication: 17 Alternative donor patients (44%) by contrast with six standard risk patients (11%) and 13 high risk patients (27%; p<0.005). The most frequent complication was a metabolic encephalopathy occurring in 18% of patients. Most of the encephalopathies were caused by either the transplant procedure, cyclosporin, systemic infections, microangiopathic thrombopathy, or by complications induced by graft versus host disease. Infections of the CNS developed in 9% of patients, cerebrovascular lesions in 3%. CONCLUSIONS: Severe neurological complications are more frequent after BMT from alternative donors. This is mainly due to increased treatment related morbidity and to more profound immunosuppression after BMT from alternative donors.
OBJECTIVE: To compare the frequency and type of neurological complications after bone marrow transplantation (BMT) with an HLA identical unrelated donor or a mismatched related donor (alternative donors) to the neurological complications after matched sibling BMT for standard and high risk leukaemia or myelodysplastic syndromes. METHODS: Retrospective analysis of consecutively treated patients with (a) BMT from alternative donors (n=39), (b) treated with matched sibling BMT for standard risk leukaemia, myelodysplastic syndromes, or aplastic anaemia (n=53), and (c) treated with matched sibling BMT for high risk leukaemia, myelodysplastic syndromes, or aplastic anaemia (n=49). RESULTS: A total of 72 neurological complications were found. Most of these occurred within the first 6 months after transplant. Thirty six patients developed a severe neurological complication: 17 Alternative donorpatients (44%) by contrast with six standard risk patients (11%) and 13 high risk patients (27%; p<0.005). The most frequent complication was a metabolic encephalopathy occurring in 18% of patients. Most of the encephalopathies were caused by either the transplant procedure, cyclosporin, systemic infections, microangiopathic thrombopathy, or by complications induced by graft versus host disease. Infections of the CNS developed in 9% of patients, cerebrovascular lesions in 3%. CONCLUSIONS: Severe neurological complications are more frequent after BMT from alternative donors. This is mainly due to increased treatment related morbidity and to more profound immunosuppression after BMT from alternative donors.
Authors: G Antonini; V Ceschin; S Morino; M Fiorelli; F Gragnani; A Mengarelli; A P Iori; W Arcese Journal: Neurology Date: 1998-05 Impact factor: 9.910
Authors: D I Marks; J O Cullis; K N Ward; S Lacey; R Syzdlo; T P Hughes; A P Schwarer; E Lutz; A J Barrett; J M Hows; J R Batchelor; J M Goldman Journal: Ann Intern Med Date: 1993-08-01 Impact factor: 25.391
Authors: D E Reece; D A Frei-Lahr; J D Shepherd; K Dorovini-Zis; R D Gascoyne; D A Graeb; J J Spinelli; M J Barnett; H G Klingemann; G P Herzig Journal: Bone Marrow Transplant Date: 1991-11 Impact factor: 5.483
Authors: N A Kernan; G Bartsch; R C Ash; P G Beatty; R Champlin; A Filipovich; J Gajewski; J A Hansen; J Henslee-Downey; J McCullough Journal: N Engl J Med Date: 1993-03-04 Impact factor: 91.245
Authors: Heather S L Jim; Brent Small; Sheri Hartman; Jamie Franzen; Shannon Millay; Kristin Phillips; Paul B Jacobsen; Margaret Booth-Jones; Joseph Pidala Journal: Cancer Date: 2011-12-02 Impact factor: 6.860
Authors: N S Majhail; J D Rizzo; S J Lee; M Aljurf; Y Atsuta; C Bonfim; L J Burns; N Chaudhri; S Davies; S Okamoto; A Seber; G Socie; J Szer; M T Van Lint; J R Wingard; A Tichelli Journal: Hematol Oncol Stem Cell Ther Date: 2012
Authors: N S Majhail; J D Rizzo; S J Lee; M Aljurf; Y Atsuta; C Bonfim; L J Burns; N Chaudhri; S Davies; S Okamoto; A Seber; G Socie; J Szer; M T Van Lint; J R Wingard; A Tichelli Journal: Bone Marrow Transplant Date: 2012-03 Impact factor: 5.483
Authors: Fuat Hakan Saner; Julia Gensicke; Steven W M Olde Damink; Goran Pavlaković; Juergen Treckmann; Marc Dammann; Gernot M Kaiser; Georgios C Sotiropoulos; Arnold Radtke; Susanne Koeppen; Susanne Beckebaum; Vito Cicinnati; Silvio Nadalin; Massimo Malagó; Andreas Paul; Christoph E Broelsch Journal: J Neurol Date: 2009-09-01 Impact factor: 4.849